# Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC)

> **NCT01129154** · PHASE2 · UNKNOWN · sponsor: **Cliniques universitaires Saint-Luc- Université Catholique de Louvain** · enrollment: 17 (estimated)

## Conditions studied

- Carcinoma, Squamous Cell

## Interventions

- **DRUG:** infusions of Panitumumab

## Key facts

- **NCT ID:** NCT01129154
- **Lead sponsor:** Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-08
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2010-08-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01129154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01129154, "Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01129154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*